Wicked Good Cardiometabolic Chat

Episode 12 explores recent updates from the 2026 ADA Scientific Sessions, highlighting for pharmacists which technologies are making waves in the diabetes space right now.

Episode 11 addresses recent changes to the AACE diabetes guidelines and what pharmacists need to do to stay informed.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.

Episode 9 dives into the landscape of obesity pharmacotherapy, detailing current therapies, clinical updates, future pipelines, and more.

Episode 8 explores the real-world evidence, clinical trial data, and overall application of finerenone for pharmacists and their patients.

Episode 7 dives into new standards of care from the American Diabetes Association and what updates are most important for pharmacists.

Episode 6 explores what pharmacists in the diabetes space need to know about outcomes data, safety, and when to escalate LDL-lowering therapy.

Episode 5 explores insulin management as well as the insulin products, doses, and administration tools all pharmacists should be familiar with for their patients with diabetes.

Episode 4 of Wicked Good Cardiometabolic Chat explores SGLT2 inhibitors and their efficacy beyond diabetes outcomes alone.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

In the first episode of the podcast, Jennifer Goldman and Hailey Choi discuss the latest FDA updates around compounded weight loss medications, clinical concerns and how pharmacists can protect their patients.